To this end, a proper stratification included specific characteristics of investigation on the cancer cells that were uncovered to be CD20- and/or CD79a-expressing B lymphocytes [26,57]; additionally, anti-CD5 was deemed important when expressed, thus allowing the identification of a clinically more aggressive CD5+ DLBCL subset [57]. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.